Sign In
Buy HYPD
Eyenovia . Common Stock Earnings Calls
| Release date | Aug 12, 2026 |
| EPS estimate | $0.230 |
| EPS actual | - |
| Revenue estimate | 1000K |
| Revenue actual | - |
| Expected change | +/- 11.35% |
| Release date | May 14, 2026 |
| EPS estimate | $1.32 |
| EPS actual | $0.260 |
| EPS Surprise | -80.30% |
| Revenue estimate | 1.467M |
| Revenue actual | 244.271K |
| Revenue Surprise | -83.35% |
| Release date | Mar 26, 2026 |
| EPS estimate | -$1.57 |
| EPS actual | -$7.76 |
| EPS Surprise | -394.27% |
| Revenue estimate | 698.333K |
| Revenue actual | 496.229K |
| Revenue Surprise | -28.94% |
| Release date | Nov 13, 2025 |
| EPS estimate | -$7.20 |
| EPS actual | $0.0500 |
| EPS Surprise | 100.69% |
| Revenue estimate | 500K |
| Revenue actual | 302.506K |
| Revenue Surprise | -39.50% |
Last 4 Quarters for Eyenovia . Common Stock
Below you can see how HYPD performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Nov 13, 2025 |
| Price on release | $4.97 |
| EPS estimate | -$7.20 |
| EPS actual | $0.0500 |
| EPS surprise | 100.69% |
| Date | Price |
|---|---|
| Nov 07, 2025 | $6.44 |
| Nov 10, 2025 | $5.82 |
| Nov 11, 2025 | $5.64 |
| Nov 12, 2025 | $5.39 |
| Nov 13, 2025 | $4.97 |
| Nov 14, 2025 | $5.01 |
| Nov 17, 2025 | $4.25 |
| Nov 18, 2025 | $4.97 |
| Nov 19, 2025 | $4.73 |
| 4 days before | -22.83% |
| 4 days after | -4.83% |
| On release day | 0.80% |
| Change in period | -26.55% |
| Release date | Mar 26, 2026 |
| Price on release | $3.49 |
| EPS estimate | -$1.57 |
| EPS actual | -$7.76 |
| EPS surprise | -394.27% |
| Date | Price |
|---|---|
| Mar 20, 2026 | $3.27 |
| Mar 23, 2026 | $3.41 |
| Mar 24, 2026 | $3.41 |
| Mar 25, 2026 | $3.70 |
| Mar 26, 2026 | $3.49 |
| Mar 27, 2026 | $3.42 |
| Mar 30, 2026 | $3.20 |
| Mar 31, 2026 | $3.45 |
| Apr 01, 2026 | $3.27 |
| 4 days before | 6.73% |
| 4 days after | -6.30% |
| On release day | -2.01% |
| Change in period | 0% |
| Release date | May 14, 2026 |
| Price on release | $3.62 |
| EPS estimate | $1.32 |
| EPS actual | $0.260 |
| EPS surprise | -80.30% |
| Date | Price |
|---|---|
| May 08, 2026 | $3.60 |
| May 11, 2026 | $3.63 |
| May 12, 2026 | $3.43 |
| May 13, 2026 | $3.50 |
| May 14, 2026 | $3.62 |
| May 15, 2026 | $3.36 |
| May 18, 2026 | $3.19 |
| May 19, 2026 | $3.44 |
| May 20, 2026 | $3.78 |
| 4 days before | 0.556% |
| 4 days after | 4.42% |
| On release day | -7.18% |
| Change in period | 5.00% |
| Release date | Aug 12, 2026 |
| Price on release | - |
| EPS estimate | $0.230 |
| EPS actual | - |
| Date | Price |
|---|---|
| Aug 04, 2026 | $2.73 |
| Aug 05, 2026 | $2.73 |
| Aug 06, 2026 | $2.67 |
| Aug 07, 2026 | $2.70 |
| Aug 10, 2026 | $2.61 |
Eyenovia . Common Stock Earnings Call Transcript Summary of Q1 2026
Hyperion DeFi reported strong Q1 2026 operational momentum as it continues to execute its DeFi strategy built around the Hyperliquid ecosystem. Management raised full-year adjusted gross profit guidance by ~20% to $5–$7M and expects cash-flow breakeven by year-end 2026. Key growth drivers this quarter included: a 140% increase in DeFi monetization (HyperCore) and >150% growth in yield enhancement strategies, driven by partnerships (Silhouette, Rysk, HyperLend/Avia, Kinetiq) and expanding HIP3 market activity. The company continues to deploy a “triple dip” HYPE strategy (stake HYPE, monetize via services, capture ecosystem upside) and has increased its HYPE and ecosystem holdings (over 2M HYPE, 10M HPL, ~1.9M KNTQ, rights to 1% Silhouette). Financial highlights: Q1 adjusted gross profit improved to $960k (up sequentially and significantly vs prior quarters), Q1 net income was $8.8M (vs Q4 net loss $39.8M) driven largely by treasury gains as HYPE price recovered; adjusted EBITDA was $19.5M. The company closed a $10M public equity offering (net ≈$9M) and had ~$16M cash as of May 11, 2026. Management emphasized continued selective partnership deployment, scaling of institutional-oriented products (e.g., Rysk premium vaults, Avia private credit), and the potential for additional upside from HIP4 outcome markets and future ecosystem rewards. Risks noted: evolving GAAP interpretations for staking/validator presentation, volatility in ecosystem awards, regulatory uncertainty around prediction/outcome markets, and ongoing transition away from legacy biotech operations.
